Evonik and Vland have signed a Joint Development Agreement as part of their existing broader partnership in the field of probiotics for animal nutrition and enzymes for industrial applications.
“The joint development agreement is expected to stimulate innovation and joint R&D activities in the field of selection, production, formulation and application of our new probiotic solution,” says Dr. Emmanuel Auer, head of Evonik’s Animal Nutrition Business Line. The combination of Vland’s core production technology and Evonik’s strong global market is expected to bring mutual benefits to both partners, including new product developments.
“Based on years’ cooperation, Vland and Evonik extend the scope to plant, livestock and aquaculture in the solution of probiotics products. After IPO, Vland focus on R&D and globalization, and strive to become a technology-driven enterprise,” says Aron Chen, CEO of the Vland group.
Vland Biotech has been established in 2005 in Qingdao (China). Vland specializes in the research and development of four main product categories which are enzymes, probiotics, vaccines and animal health products.